<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00185796</url>
  </required_header>
  <id_info>
    <org_study_id>BMT168</org_study_id>
    <secondary_id>95130</secondary_id>
    <secondary_id>BMT168</secondary_id>
    <secondary_id>13680</secondary_id>
    <nct_id>NCT00185796</nct_id>
  </id_info>
  <brief_title>TLI &amp; ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD</brief_title>
  <official_title>Total Lymphoid Irradiation and Anti-Thymocyte Globulin as Conditioning for Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for the Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      To evaluate the feasibility and safety of TLI/ATG conditioning for allogeneic HCT for elderly
      patients with advanced stage MDS and MPD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total Lymphoid Irradiation and Anti-Thymocyte Globulin as Conditioning for Non-Myeloablative
      Allogeneic Hematopoietic Cell Transplantation for the Treatment of Myelodysplastic Syndromes
      and Myeloproliferative Disorders (except CML). To evaluate the feasibility and safety of
      TLI/ATG conditioning for allogeneic HCT for elderly patients or those with co-morbid
      conditions that preclude myeloablative transplantation for advanced stage MDS and MPD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To improve survival outcome for selected patients with advanced stages of MDS and MPD with non-myeloablative allogeneic HCT from related and unrelated donors.</measure>
    <time_frame>7/15/2017</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the feasibility and safety of TLI/ATG conditioning for allogeneic HCT for elderly patients or those with co-morbid conditions that preclude myeloablative transplantation for advanced stage MDS and MPD.</measure>
    <time_frame>7/15/2017</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate myeloid and platelet engraftment.</measure>
    <time_frame>7/15/2017</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the incidence of acute and chronic GVHD.</measure>
    <time_frame>7/15/2017</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the rate of primary and secondary graft failure.</measure>
    <time_frame>7/15/2017</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the rate of relapse, survival and event-free survival.</measure>
    <time_frame>7/15/2017</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate if DLI can be used safely in patients with mixed chimerism.</measure>
    <time_frame>7/15/2017</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Myeloproliferative Disorders</condition>
  <condition>Blood Cancer</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>TLI/ATG conditioning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lymphoid irradiation and anti-thymocyte globulin (TLI/ATG).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total Lymphoid Irradiation (TLI)</intervention_name>
    <description>TLI is administered ten times in 120cGy fractions on day -11 through day -7 and day -4 through day -1</description>
    <arm_group_label>TLI/ATG conditioning</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Anti-Thymocyte Globulin as Conditioning (ATG)</intervention_name>
    <description>Thymoglobulin will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg. Thymoglobulin doses will be based on the adjusted ideal body weight if the patient is greater than or equal to 15 kg over ideal body weight.</description>
    <arm_group_label>TLI/ATG conditioning</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        GENERAL INCLUSION CRITERIA

          -  General inclusion criteria must include at least one of the following:

               -  Patients aged &gt; 49 and &lt; 75 years with MDS or MPD

               -  Patients aged &lt; 49 years at high risk for regimen related toxicity using standard
                  high dose regimens. Factors considered high risk include pre-existing conditions
                  such as a chronic disease affecting kidneys, liver, lungs, or heart.

               -  Patients with secondary MDS following a prior autologous transplant.

          -  An HLA-identical related or an HLA-matched unrelated donor is available. ABO
             incompatibility is acceptable.

          -  A signed informed consent form.

        MYELODYSPLASTIC SYNDROME CRITERIA

          -  Diagnosis of MDS classifiable by the FAB system as refractory anemia (RA), refractory
             anemia with ringed sideroblasts (RARS), chronic myelomonocytic leukemia (CMML),
             refractory anemia with excess blasts (RAEB), and MDS transformed to acute leukemia.

          -  Patients with advanced MDS must be cytoreduced to &lt; 10% marrow blasts prior to
             receiving conditioning with TLI/ATG. Less than 10% marrow blasts must be documented by
             marrow examination within 1 month of starting conditioning. The cytoreductive regimen
             will be determined by referring centers.

          -  Patients with evolution to AML are required to be in a complete remission as defined
             by a blast count of less than 5% in a marrow aspirate with adequate cellularity.
             Presence of residual dysplastic features following cytoreductive therapy is
             acceptable.

          -  All patients with high risk disease, for example &quot;intermediate-2&quot; or &quot;high risk&quot;
             disease by the IPSS score. Other selected patients with a lower IPSS score may be
             considered but only after discussion with the BMT attending physicians, as a group,
             and the PI of the study.

        MYELOPROLIFERATIVE DISORDERS

          -  Myeloproliferative disorders to be included:

               -  Philadelphia chromosome-negative CML.

               -  Patients with polycythemia vera with persistent thrombotic or hemorrhagic
                  complications despite conventional therapy, or who have progressed to
                  post-polycythemic marrow fibrosis.

               -  Patients with essential thrombocythemia with persistent thrombotic or hemorrhagic
                  complications despite conventional therapy, or who have progressed to
                  myelofibrosis.

               -  Patients with agnogenic myeloid metaplasia with high risk disease, for example
                  &quot;intermediate&quot; or &quot;high risk&quot; according to the Lille Scoring System.

          -  Patients must be cytoreduced to &lt; 10% marrow blasts. Less than 10% marrow blasts must
             be documented by marrow examination within 1 month of initiation of TLI/ATG. The
             cytoreductive regimen will be determined by referring centers.

          -  Patients with evolution to AML are required to be in a complete remission as defined
             by a blast count of less than 5% in a marrow aspirate with adequate cellularity.
             Presence of residual dysplastic features following cytoreductive therapy is
             acceptable.

        INCLUSION CRITERIA - RELATED DONORS

          -  Related to the patient and is genotypically or phenotypically HLA-identical.

          -  Donor age &lt; 75 unless cleared by P.I

          -  Capable of giving written, informed consent.

          -  Donor must consent to PBSC mobilization with G-CSF and apheresis

        INCLUSION CRITERIA - UNRELATED DONORS

          -  Donors must be HLA-matched as defined by the following criteria:

               -  Matched for HLA-DRB1 and DQB1 by high resolution typing.

               -  Serologic match for all recognized HLA-A, HLA-B, and HLA-C antigens, and
                  molecular match for at least 5 of 6 HLA-A, HLA-B, or HLA-C antigens by high
                  resolution typing.

          -  Donor must consent to PBSC mobilization with G-CSF and apheresis. Bone marrow
             unrelated donors are not eligible for this protocol.

        Exclusion Criteria:GENERAL EXCLUSION CRITERIA

          -  Organ dysfunction as defined by the following:

               -  Renal: Patients with a normal creatinine are eligible for study without the need
                  for a 24 hr urine collection for creatinine clearance. Patients with an elevated
                  creatinine require a 24 hr urine collection. If the creatinine clearance is &lt; 50
                  ml/min patients will be determined for inclusion on a case by case basis.

               -  Cardiac: Ejection fraction &lt; 40%, symptomatic congestive heart failure requiring
                  therapy, poorly controlled cardiac arrythmias, or poorly controlled hypertension
                  with inability to maintain a steady-state blood pressure of 150/90.

               -  Pulmonary: Requirement for supplemental oxygen administration, or pulmonary
                  function testing showing (1) DLCO &lt; 50% of predicted, (2) TLC &lt; 30%, or (3) FEV1
                  &lt; 30%.

               -  Hepatic: Patients with clinical or laboratory evidence of liver disease would be
                  evaluated for the cause of liver disease, its clinical severity in terms of liver
                  function and degree of portal hypertension. Patients will be excluded if they are
                  found to have fulminant liver failure, cirrhosis if the liver with evidence of
                  portal hypertension, alcoholic hepatitis, esophageal varices, a history of
                  bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic
                  synthetic dysfunction evidenced by prolongation of the prothrombin time, ascites
                  related to portal hypertension, bacterial or fungal liver abscess. Biliary
                  obstruction, chronic viral hepatitis with total serum bilirubin &gt; 3 mg/dl, and
                  symptomatic biliary disease.

          -  Bone marrow documenting blast count &gt;=10%.

          -  Presence of active of non-hematologic malignancy (except localized non-melanoma skin
             malignancies) or hematologic malignancy other than MDS or MPD as listed in inclusion
             criteria.

          -  Active CNS involvement of disease.

          -  Karnofsky performance score &lt;= 60% or Lansky-Play Performance score &lt;50 for pediatric
             patients.

          -  Life expectancy severely limited by diseases other than malignancy.

          -  Fungal infections with radiological progression despite with an amphotericin product
             or active triazole for &gt; 1 month.

          -  Active bacterial infection.

          -  Patients of fertile age who refuse contraception for a twelve month period
             post-transplant.

          -  Pregnant or lactating females.

          -  HIV seropositivity.

          -  Severe psychological illness.

        EXCLUSION CRITERIA - RELATED DONORS

          -  Identical twin

          -  Any contra-indication to the administration of subcutaneous G-CSF at a dose of
             16mg/kg/d for five consecutive days

          -  Serious medical or psychological illness

          -  Pregnant or lactating females

          -  Prior malignancy within the preceding five years, with the exception of non-melanoma
             skin cancers.

          -  HIV seropositivity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>49 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Lowsky</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>March 16, 2015</last_update_submitted>
  <last_update_submitted_qc>March 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Robert Lowsky</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

